News Archive

SomaLogic and Otsuka scientists publish paper describing therapeutic potential of novel SOMAmer reagent for rheumatoid arthritis

In a “Fast Track” article published in the journal Nucleic Acid Therapeutics, researchers from SomaLogic and Otsuka Pharmaceutical describe a series of studies that demonstrate that treatment with a novel Slow Off-rate Modified Aptamer (SOMAmer) molecule can significantly delay the onset and reduce the severity of rheumatoid arthritis in a cynomolgus monkey model of the disease.

read more

SomaLogic named “Company of the Year” at Colorado BioScience Association’s 2015 Awards Dinner

SomaLogic was recognized as “Company of the Year” by the Colorado BioScience Association at its 12th Annual Awards Dinner in Denver, CO, on November 12, 2015. SomaLogic was cited for developing “a new proteomics technology with a mission to leverage its proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare.”

read more

SomaLogic joins UK Dementias Research Platform

SomaLogic announced today that is a launch partner of the Medical Research Council’s UK Dementias Research Platform, a $27 million public-private partnership set up to speed up research into dementias. The collaboration aims to enable earlier detection, improved treatment and, ultimately, prevention of the disease, by looking not just at what is going wrong in the brain, but at the brain in the context of the whole body.

read more

SomaLogic scientists and colleagues publish two papers describing IL-6 SOMAmers

In a pair of papers published in the Journal of Biological Chemistry, a group of SomaLogic researchers and their colleagues at Otsuka Pharmaceuticals and Emerald Bio describe the development of new SOMAmer reagents that can block signaling by interleukin-6 (a critical protein involved in inflammation and cancer), as well as the structural interaction of the two molecules.

read more